Monitor progress toward Phase 3 PARAGON trial initiation and any subsequent financing events, as the company's cash position ($0.2M) suggests a capital raise is imminent. The patent news alone is unlikely to move the stock materially without nearer-term catalysts or a funding announcement.
Price Chart
Executive Summary
NeuroSense Therapeutics received a Japanese patent (No. 7857044) for its lead ALS drug candidate PrimeC, extending intellectual property protection through 2042. This builds on prior patent grants in the US, Australia, and Brazil, strengthening the company's global IP portfolio. However, the company has negligible cash ($0.2M) and no revenue, with substantial doubt about its ability to continue as a going concern, which tempers the materiality of this patent news.
Key Facts
- Japanese Patent 7857044 issued for PrimeC composition covering ciprofloxacin and celecoxib formulation
- Patent protection extends through 2042, includes 17 claims
- Japan is a key strategic pharmaceutical market per CEO Alon Ben-Noon
- Patent follows recent grants in US, Australia, and Brazil
- Company has only $0.2 million cash and no revenue (per 20-F cross-filing)
- Company is preparing for a Phase 3 pivotal trial (PARAGON) with FDA clearance
Financial Impact
No direct financial impact from patent grant; strengthens IP protection but no revenue or near-term cash flow changes
Risk Factors
- Cash runway extremely limited with $0.2M on hand and no revenue
- Substantial doubt about going concern as stated in prior 20-F filing
- Phase 3 trial still not initiated; regulatory and clinical risks remain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-066582 |
| Document: ea0294098-6k_neurosense.htm | 0001213900-26-066582 |
| Document: 0001213900-26-066582-index-headers.html | 0001213900-26-066582 |
| Document: 0001213900-26-066582-index.html | 0001213900-26-066582 |
| Document: 0001213900-26-066582.txt | 0001213900-26-066582 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 19w ago | 6-K | $0.1451 $0.0500 | ▼ −65.54% | ▼ −69.35% | — |
Jun 8, 2026 20w ago | 6-K | $0.1500 $0.0456 | ▼ −69.60% | ▼ −72.65% | — |
Apr 28, 2026 25w ago | 6-K | $0.2080 $0.0601 | ▼ −71.11% | ▼ −75.10% | — |
Apr 24, 2026 26w ago | 6-K | $0.2080 $0.0811 | ▼ −61.01% | ▼ −66.09% | — |
Apr 6, 2026 29w ago | 6-K | $0.2080 $0.0733 | ▼ −64.76% | ▼ −78.23% | — |
Apr 3, 2026 29w ago | 6-K | $0.2080 $0.0733 | ▲ +64.76% | ▲ +78.23% | — |
Apr 1, 2026 29w ago | 3 | $0.2080 $0.0630 | ▼ −69.71% | ▼ −83.87% | — |
Mar 31, 2026 30w ago | 20-F / 6-K | $0.2080 $0.2080 | · 0.00% | ▼ −13.20% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers